Axial Spondyloarthritis – Unmet Need – Unmet Need – Nonradiographic Axial Spondyloarthritis (US/EU)
TNF-alpha inhibitors, such as AbbVie’s Humira, Amgen’s Enbrel, Johnson & Johnson Innovative Medicine’s Simponi, and UCB’s Cimzia, are approved for the treatment of nonradiographic axial spondyloarthritis (nr-AxSpA) in Europe. While Cimzia is the only FDA-approved TNF-alpha inhibitor for nr-AxSpA in the United States, the other drugs in the class are increasingly used off-label. Alongside TNF-α inhibitors, IL-17 inhibitors (like Novartis’s Cosentyx, Eli Lilly’s Taltz, the recently approved Bimzelx [UCB]) are also used to treat nr-AxSpA in both regions. Another interesting option for nr-AxSpA is AbbVie’s oral JAK inhibitor, Rinvoq. Xeljanz may be used off-label for the indication, but evidence supporting its use remains limited. In this report, we examine areas of unmet need in the treatment of nr-AxSpA, including short-term efficacy, improvement in patient-reported quality of life, mechanism of action, safety and tolerability, delivery, and price. With quantitative insight into U.S. and European rheumatologists’ assessment of the unmet need in nr-AxSpA, we discuss the commercial opportunities for this difficult-to-diagnose indication and how emerging therapies can capitalize on these opportunities.
QUESTIONS ANSWERED
- What are the treatment drivers and goals for nr-AxSpA?
- Which drug attributes are key influences, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for nr-AxSpA?
- What are the prevailing areas of unmet need and opportunity in nr-AxSpA?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European rheumatologists for a hypothetical new nr-AxSpA drug?
PRODUCT DESCRIPTION
Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:
- Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
- Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
- Analyze market scenarios for different target product profiles using the TPP Simulator.
Key feature
Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 31 European rheumatologists fielded in January 2025
Key drugs: Humira, Cimzia, Cosentyx, Taltz, Rinvoq, Xeljanz, NSAIDs
